{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:27Z","timestamp":1786977987496,"version":"build-2736575974"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":554,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Senior Research Fellowship","award":["SRF-2018-11-ST2-004"],"award-info":[{"award-number":["SRF-2018-11-ST2-004"]}]},{"name":"the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre"},{"name":"UKRI Future Leaders Fellowship","award":["MR\/S017968\/1"],"award-info":[{"award-number":["MR\/S017968\/1"]}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Although oral bisphosphonates (BP) are commonly used, there is conflicting evidence for their safety in the elderly. Safety concerns might trump BP use in older patients with complex health needs. Our study evaluated the safety of BP, focusing on severe acute kidney injury (AKI), gastrointestinal ulcer (GI ulcer), osteonecrosis of the jaw (ONJ), and femur fractures. We used UK primary care data (Clinical Practice Research Datalink [CPRD GOLD]), linked to hospital (Hospital Episode Statistics [HES] inpatient) and ONS mortality data. We included all patients aged &amp;gt;65 with complex health needs and no BP use in the year before study start (January 1, 2010). Complex health needs were defined in three cohorts: an electronic frailty index score \u22653 (frailty cohort), one or more unplanned hospitalization\/s (hospitalization cohort); and prescription of \u226510 different medicines in 2009 (polypharmacy cohort). Incidence rates were calculated for all outcomes. Subsequently, all individuals who experienced AKI or GI ulcer anytime during follow-up were included for Self-Controlled Case Series (SCCS) analyses. Incidence rate ratios (IRRs) were estimated separately for AKI and GI ulcer, comparing event rates between BP-exposed and unexposed time windows. No SCCS were conducted for ONJ and femur fractures. We identified 94,364 individuals in the frailty cohort, as well as 78,184 and 95,621 persons in the hospitalization and polypharmacy cohorts. Of those, 3023, 1950, and 2992 individuals experienced AKI and 1403, 1019, and 1453 had GI ulcer\/s during follow-up, respectively. Age-adjusted SCCS models found evidence of increased risk of AKI associated with BP use (frailty cohort: IRR 1.65; 95% confidence interval [CI], 1.25\u20132.19), but no association with GI ulcers (frailty cohort: IRR 1.24; 95% CI, 0.86\u20131.78). Similar results were obtained for the hospitalization and polypharmacy cohorts. Our study found a 50% to 65% increased risk of AKI associated with BP use in elderly patients with complex health needs. Future studies should further investigate the risk\u2013benefit of BP use in these patients. \u00a9 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4573","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T09:28:49Z","timestamp":1652779729000},"page":"1270-1278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oral Bisphosphonates Are Associated With Increased Risk of Severe Acute Kidney Injury in Elderly Patients With Complex Health Needs: A Self-Controlled Case Series in the United Kingdom"],"prefix":"10.1093","volume":"37","author":[{"given":"Tetsuro","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-0110","authenticated-orcid":false,"given":"Annika M.","family":"J\u00f6dicke","sequence":"additional","affiliation":[{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0940-9211","authenticated-orcid":false,"given":"Danielle E.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6504-3253","authenticated-orcid":false,"given":"Ruth H.","family":"Keogh","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":false,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[{"name":"Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"2 Suppl","key":"2024012713592388000_jbmr4573-bib-0001","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2008.12.003","article-title":"Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis","volume":"122","author":"Bilezikian","year":"2009","journal-title":"Am J Med"},{"key":"2024012713592388000_jbmr4573-bib-0002","author":"National Institute for Health and Care Excellence"},{"issue":"1","key":"2024012713592388000_jbmr4573-bib-0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","article-title":"Safety issues with bisphosphonate therapy for osteoporosis","volume":"53","author":"Suresh","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2024012713592388000_jbmr4573-bib-0004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11585470-000000000-00000","article-title":"Safety of long-term bisphosphonate therapy for the management of osteoporosis","volume":"71","author":"Lewiecki","year":"2011","journal-title":"Drugs"},{"issue":"9","key":"2024012713592388000_jbmr4573-bib-0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis","volume":"30","author":"Strampel","year":"2007","journal-title":"Drug Saf"},{"issue":"1","key":"2024012713592388000_jbmr4573-bib-0006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J Cell Biochem"},{"issue":"9","key":"2024012713592388000_jbmr4573-bib-0007","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00256-011-1164-9","article-title":"Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies","volume":"40","author":"Reid","year":"2011","journal-title":"Skeletal Radiol"},{"issue":"17","key":"2024012713592388000_jbmr4573-bib-0008","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2024012713592388000_jbmr4573-bib-0009","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"2024012713592388000_jbmr4573-bib-0010","author":"CPRD"},{"issue":"3","key":"2024012713592388000_jbmr4573-bib-0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2024012713592388000_jbmr4573-bib-0012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"key":"2024012713592388000_jbmr4573-bib-0013","doi-asserted-by":"crossref","first-page":"104038","DOI":"10.1016\/j.ijmedinf.2019.104038","article-title":"CPRD GOLD and linked ONS mortality records: reconciling guidelines","volume":"136","author":"Delmestri","year":"2020","journal-title":"Int J Med Inform"},{"key":"2024012713592388000_jbmr4573-bib-0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2369-14-58","article-title":"The accuracy of diagnostic coding for acute kidney injury in England\u2014a single centre study","volume":"14","author":"Tomlinson","year":"2013","journal-title":"BMC Nephrol"},{"key":"2024012713592388000_jbmr4573-bib-0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/CLEP.S146757","article-title":"Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis","volume":"10","author":"Mansfield","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"4","key":"2024012713592388000_jbmr4573-bib-0016","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jclinepi.2009.07.001","article-title":"Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length","volume":"63","author":"Gardarsdottir","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2024012713592388000_jbmr4573-bib-0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics"},{"issue":"5","key":"2024012713592388000_jbmr4573-bib-0018","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1467-9876.2006.00554.x","article-title":"Semiparametric analysis of case series data","volume":"55","author":"Farrington","year":"2006","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"2024012713592388000_jbmr4573-bib-0019","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"2024012713592388000_jbmr4573-bib-0020","author":"Weldeselassie","year":"2020"},{"issue":"8","key":"2024012713592388000_jbmr4573-bib-0021","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/ki.2012.227","article-title":"Oral bisphosphonate use in the elderly is not associated with acute kidney injury","volume":"82","author":"Shih","year":"2012","journal-title":"Kidney Int"},{"issue":"5","key":"2024012713592388000_jbmr4573-bib-0022","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024012713592388000_jbmr4573-bib-0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/eurheartj\/ehu263","article-title":"Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study","volume":"36","author":"Brauer","year":"2015","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"2024012713592388000_jbmr4573-bib-0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pds.3846","article-title":"The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies","volume":"25","author":"Brauer","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024012713592388000_jbmr4573-bib-0025","doi-asserted-by":"crossref","first-page":"e4388","DOI":"10.1136\/bmj.e4388","article-title":"Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs","volume":"345","author":"Douglas","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2024012713592388000_jbmr4573-bib-0026","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","article-title":"Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis","volume":"53","author":"Coca","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2024012713592388000_jbmr4573-bib-0027","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.2009060636","article-title":"Acute kidney injury associates with increased long-term mortality","volume":"21","author":"Lafrance","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2024012713592388000_jbmr4573-bib-0028","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000337487","article-title":"Acute kidney injury and mortality in hospitalized patients","volume":"35","author":"Wang","year":"2012","journal-title":"Am J Nephrol"},{"key":"2024012713592388000_jbmr4573-bib-0029","doi-asserted-by":"crossref","first-page":"2151459320920088","DOI":"10.1177\/2151459320920088","article-title":"Predictors of acute kidney injury after hip fracture in older adults","volume":"11","author":"Brauner Christensen","year":"2020","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"1","key":"2024012713592388000_jbmr4573-bib-0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12882-017-0437-5","article-title":"Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury","volume":"18","author":"Porter","year":"2017","journal-title":"BMC Nephrol"},{"key":"2024012713592388000_jbmr4573-bib-0031","first-page":"325","article-title":"Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2024012713592388000_jbmr4573-bib-0032","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00198-014-2647-z","article-title":"Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study","volume":"25","author":"Peng","year":"2014","journal-title":"Osteoporos Int"},{"key":"2024012713592388000_jbmr4573-bib-0033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2318-13-36","article-title":"The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study","volume":"13","author":"Knopp-Sihota","year":"2013","journal-title":"BMC Geriatr"},{"key":"2024012713592388000_jbmr4573-bib-0034","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate\u2014the fracture intervention trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"2024012713592388000_jbmr4573-bib-0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2024012713592388000_jbmr4573-bib-0036","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.clinthera.2015.03.018","article-title":"Gastrointestinal events among patients initiating osteoporosis therapy: a retrospective administrative claims database analysis","volume":"37","author":"Modi","year":"2015","journal-title":"Clin Ther"},{"issue":"11","key":"2024012713592388000_jbmr4573-bib-0037","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1365-2036.2009.03989.x","article-title":"Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study","volume":"29","author":"Etminan","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2024012713592388000_jbmr4573-bib-0038","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2024012713592388000_jbmr4573-bib-0039","doi-asserted-by":"crossref","first-page":"i3365","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"issue":"12","key":"2024012713592388000_jbmr4573-bib-0040","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s00198-019-05112-5","article-title":"Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure","volume":"30","author":"Lo","year":"2019","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024012713592388000_jbmr4573-bib-0041","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","article-title":"Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink","volume":"31","author":"Morley","year":"2020","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4573","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/7\/1270\/55458816\/jbmr4573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/7\/1270\/55458816\/jbmr4573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:08:57Z","timestamp":1710328137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/37\/7\/1270-1278\/7516766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4573","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4573\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4573\/v2\/review3","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2021-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}